Compare Aurobindo Pharma with Procter & Gamble Health - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs PROCTER & GAMBLE HEALTH - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

PROCTER & GAMBLE HEALTH 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA PROCTER & GAMBLE HEALTH AUROBINDO PHARMA/
PROCTER & GAMBLE HEALTH
 
P/E (TTM) x 18.7 47.1 39.6% View Chart
P/BV x 3.8 5.0 75.9% View Chart
Dividend Yield % 0.3 9.4 2.9%  

Financials

 AUROBINDO PHARMA   PROCTER & GAMBLE HEALTH
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
PROCTER & GAMBLE HEALTH
Dec-18
AUROBINDO PHARMA/
PROCTER & GAMBLE HEALTH
5-Yr Chart
Click to enlarge
High Rs8303,549 23.4%   
Low Rs5271,301 40.5%   
Sales per share (Unadj.) Rs333.9511.4 65.3%  
Earnings per share (Unadj.) Rs40.461.3 65.8%  
Cash flow per share (Unadj.) Rs51.874.0 69.9%  
Dividends per share (Unadj.) Rs2.50440.00 0.6%  
Dividend yield (eoy) %0.418.1 2.0%  
Book value per share (Unadj.) Rs237.1927.8 25.6%  
Shares outstanding (eoy) m585.9116.60 3,529.6%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.04.7 42.9%   
Avg P/E ratio x16.839.6 42.5%  
P/CF ratio (eoy) x13.132.8 40.0%  
Price / Book Value ratio x2.92.6 109.5%  
Dividend payout %6.2717.9 0.9%   
Avg Mkt Cap Rs m397,56940,257 987.6%   
No. of employees `00017.91.1 1,574.5%   
Total wages/salary Rs m25,8491,313 1,969.1%   
Avg. sales/employee Rs Th10,956.97,486.7 146.4%   
Avg. wages/employee Rs Th1,447.71,157.6 125.1%   
Avg. net profit/employee Rs Th1,324.3897.2 147.6%   
INCOME DATA
Net Sales Rs m195,6368,490 2,304.3%  
Other income Rs m1,553244 636.8%   
Total revenues Rs m197,1898,734 2,257.8%   
Gross profit Rs m39,5191,482 2,667.3%  
Depreciation Rs m6,680211 3,162.6%   
Interest Rs m2,6260-   
Profit before tax Rs m31,7671,514 2,097.8%   
Minority Interest Rs m270-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-88166 -1,342.4%   
Tax Rs m7,269563 1,292.2%   
Profit after tax Rs m23,6451,017 2,324.1%  
Gross profit margin %20.217.5 115.8%  
Effective tax rate %22.937.1 61.6%   
Net profit margin %12.112.0 100.9%  
BALANCE SHEET DATA
Current assets Rs m153,64515,343 1,001.4%   
Current liabilities Rs m120,4291,960 6,143.7%   
Net working cap to sales %17.0157.6 10.8%  
Current ratio x1.37.8 16.3%  
Inventory Days Days13549 277.4%  
Debtors Days Days6428 223.9%  
Net fixed assets Rs m103,9091,209 8,592.5%   
Share capital Rs m586166 353.0%   
"Free" reserves Rs m138,32215,235 907.9%   
Net worth Rs m138,90815,401 901.9%   
Long term debt Rs m1,8000-   
Total assets Rs m264,54417,595 1,503.6%  
Interest coverage x13.1NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.70.5 153.3%   
Return on assets %9.95.8 171.7%  
Return on equity %17.06.6 257.7%  
Return on capital %23.810.3 232.4%  
Exports to sales %49.60-   
Imports to sales %18.80-   
Exports (fob) Rs m97,091NA-   
Imports (cif) Rs m36,741NA-   
Fx inflow Rs m97,3161,636 5,947.3%   
Fx outflow Rs m40,5894,368 929.2%   
Net fx Rs m56,727-2,732 -2,076.6%   
CASH FLOW
From Operations Rs m16,220-1,304 -1,244.1%  
From Investments Rs m-28,76812,697 -226.6%  
From Financial Activity Rs m19,191-301 -6,386.2%  
Net Cashflow Rs m6,65611,093 60.0%  

Share Holding

Indian Promoters % 54.1 0.0 -  
Foreign collaborators % 0.0 51.8 -  
Indian inst/Mut Fund % 8.0 18.2 43.7%  
FIIs % 27.7 1.0 2,770.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 29.1 35.1%  
Shareholders   69,601 28,591 243.4%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   ELDER PHARMA  FDC LTD.  SHASUN PHARMA  DISHMAN PHARMA  TTK HEALTHCARE  

Compare AUROBINDO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Flat; Power and Telecom Stocks Witness Buying(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

PROCTER & GAMBLE HEALTH Share Price Up by 7%; BSE HEALTHCARE Index Down 0.3% (Market Updates)

Aug 7, 2020 | Updated on Aug 7, 2020

PROCTER & GAMBLE HEALTH share price is trading up by 7% and its current market price is Rs 4,703. The BSE HEALTHCARE is down by 0.3%. The top gainers in the BSE HEALTHCARE Index is PROCTER & GAMBLE HEALTH (up 6.9%). The top losers are DR. REDDYS LAB and STRIDES PHARMA SCIENCE (down 0.1%).

DR. REDDYS LAB at All Time High; BSE HEALTHCARE Index Down 0.1% (Market Updates)

Aug 7, 2020 | Updated on Aug 7, 2020

DR. REDDYS LAB share price has hit an all time high at Rs 4,707 (up 0.7%). The BSE HEALTHCARE Index is down by 0.1%. Among the top gainers in the BSE HEALTHCARE Index today are DR. REDDYS LAB (up 0.7%) and ABBOTT INDIA (up 0.1%). The top losers include CIPLA (down 0.1%) and PFIZER (down 0.2%).

GRANULES INDIA at All Time High; BSE HEALTHCARE Index Up 0.6% (Market Updates)

Aug 7, 2020 | Updated on Aug 7, 2020

GRANULES INDIA share price has hit an all time high at Rs 329 (down 0.7%). The BSE HEALTHCARE Index is up by 0.6%. Among the top gainers in the BSE HEALTHCARE Index today are GRANULES INDIA (down 0.2%) and ABBOTT INDIA (up 0.2%). The top losers include J.B.CHEMICALS and SUN PHARMA ADV. RES. (down 0.1%).

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

These 5 Smallcaps Deserve a Place in Your Coffee Can Portfolio(Profit Hunter)

Jul 28, 2020

When it comes to quality stocks, doing less is more.

Before You Buy Your First Electric Vehicle Consider Buying this Stock(Profit Hunter)

Jul 29, 2020

As competition intensifies in the electric vehicle space, only few will create huge wealth over the years.

How to Buy Gold and Silver(Fast Profits Daily)

Jul 27, 2020

In this video I'll show you how to buy bullion the right way.

Elon Musk Gives Us a Trading Opportunity(Fast Profits Daily)

Jul 28, 2020

Elon Musk made a statement recently which I believe, gives us a fast profit trading opportunity.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Aug 7, 2020 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - SANOFI INDIA COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS